DermTech Statistics
Total Valuation
DermTech has a market cap or net worth of $20.27 million. The enterprise value is $15.33 million.
| Market Cap | 20.27M |
| Enterprise Value | 15.33M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DermTech has 34.62 million shares outstanding. The number of shares has increased by 8.66% in one year.
| Shares Outstanding | 34.62M |
| Shares Change (YoY) | +8.66% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 4.24% |
| Owned by Institutions (%) | 21.09% |
| Float | 33.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.33 |
| Forward PS | 1.11 |
| PB Ratio | 0.35 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 0.95.
| Current Ratio | 4.59 |
| Quick Ratio | 4.60 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -124.00% and return on invested capital (ROIC) is -92.98%.
| Return on Equity (ROE) | -124.00% |
| Return on Assets (ROA) | -67.90% |
| Return on Capital (ROIC) | -92.98% |
| Revenue Per Employee | $74,252 |
| Profits Per Employee | -$489,748 |
| Employee Count | 206 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 10.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.01% in the last 52 weeks. The beta is 2.56, so DermTech's price volatility has been higher than the market average.
| Beta (1Y) | 2.56 |
| 52-Week Price Change | -84.01% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 36.13 |
| Average Volume (30 Days) | 296,562 |
Short Selling Information
The latest short interest is 3.08 million, so 8.91% of the outstanding shares have been sold short.
| Short Interest | 3.08M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 8.91% |
| Short % of Float | 9.29% |
| Short Ratio (days to cover) | 16.36 |
Income Statement
In the last 12 months, DermTech had revenue of $15.30 million and -$100.89 million in losses. Loss per share was -$3.09.
| Revenue | 15.30M |
| Gross Profit | 276,000 |
| Operating Income | -103.74M |
| Pretax Income | -100.89M |
| Net Income | -100.89M |
| EBITDA | -95.04M |
| EBIT | -100.89M |
| Loss Per Share | -$3.09 |
Balance Sheet
The company has $59.33 million in cash and $54.39 million in debt, giving a net cash position of $4.94 million or $0.14 per share.
| Cash & Cash Equivalents | 59.33M |
| Total Debt | 54.39M |
| Net Cash | 4.94M |
| Net Cash Per Share | $0.14 |
| Equity / Book Value | 57.18M |
| Book Value Per Share | 1.65 |
| Working Capital | 48.31M |
Cash Flow
In the last 12 months, operating cash flow was -$76.98 million and capital expenditures -$902,000, giving a free cash flow of -$77.88 million.
| Operating Cash Flow | -76.98M |
| Capital Expenditures | -902,000 |
| Free Cash Flow | -77.88M |
| FCF Per Share | -$2.39 |
Margins
Gross margin is 1.80%, with operating and profit margins of -678.21% and -659.57%.
| Gross Margin | 1.80% |
| Operating Margin | -678.21% |
| Pretax Margin | -659.57% |
| Profit Margin | -659.57% |
| EBITDA Margin | -621.35% |
| EBIT Margin | -659.57% |
| FCF Margin | -509.16% |
Dividends & Yields
DermTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.66% |
| Shareholder Yield | -8.66% |
| Earnings Yield | -497.76% |
| FCF Yield | -384.25% |
Analyst Forecast
The average price target for DermTech is $1.38, which is 135.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.38 |
| Price Target Difference | 135.74% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on August 30, 2019. It was a reverse split with a ratio of 1:2.
| Last Split Date | Aug 30, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
DermTech has an Altman Z-Score of -6.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.81 |
| Piotroski F-Score | 3 |